title: [Manifestation of multiple sclerosis under treatment with infliximab for intermediate uveitis].
authors.affiliation: Neurologische Klinik und Poliklinik, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil Bochum GmbH, Bürkle-de-la-Camp-Platz 1, 44789, Bochum. matthias.sczesny@bergmannsheil.de
authors.forename: M
authors.initials: M
authors.lastname: Sczesny-Kaiser
authors.forename: M
authors.initials: M
authors.lastname: Veit
authors.forename: C
authors.initials: C
authors.lastname: Heinz
authors.forename: A
authors.initials: A
authors.lastname: Heiligenhaus
authors.forename: M
authors.initials: M
authors.lastname: Tegenthoff
authors.forename: P
authors.initials: P
authors.lastname: Schwenkreis
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000175:diagnosis*; D016896:Treatment Outcome; D015867:Uveitis, Intermediate / Q000150:complications* / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab